与623名接受复合因子VIIa治疗心脏手术出血的患者的死亡率相关的特征
Allianna Mitchell1, Kaitlyn Lorbiecki1, Cheen Alkhatib2
1University of Kansas Medical Center, Kansas City, KS.
Journal of cardiothoracic and vascular anesthesia
|August 12, 2025
概括
在心脏手术中使用活性复合因子VII (rFVIIa) 没有显示出剂量依赖的死亡率. 在这项研究中,患者的特征,而不是rFVIIa剂量,与生存结果有关.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 外科手术的结果
背景情况:
- 活性复合因子VII (rFVIIa) 是用于心脏手术出血的非标签.
- 鉴于出血导致的高死亡率,评估rFVIIa的血栓风险至关重要.
研究的目的:
- 分析接受非常低剂量的rFVIIa的心脏手术患者的死亡率特征.
- 在高风险的手术群体中评估rFVIIa的安全性和有效性.
主要方法:
- 追溯的队列研究.
- 分析了7724名心脏手术患者 (2012-2025年),其中623人接受rFVIIa (平均剂量为18μg/kg).
- rFVIIa在0.5至1毫克的量中进行术前治疗.
主要成果:
- 在幸存者和非幸存者 (2.17对2.79毫克) 之间的中位数rFVIIa剂量没有显著差异.
- 与手术类型相关的死亡率 (心脏移植,VAD,复杂手术:29.5%),急诊手术,心脏性休克,更长的绕道时间和输血产品.
- 在rFVIIa使用和中风或感染之间没有发现任何关联.
结论:
- rFVIIa可以给心脏手术患者使用.
- 接受rFVIIa的患者的死亡率特征与未接受rFVIIa的患者相似.
- 患者特异性因素,而不是rFVIIa剂量,是结果的关键决定因素.
相关概念视频
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Low-Molecular-Weight Heparins
903
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
903
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Venous Thrombosis IV: Nursing Management
23
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
23
Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K


